Quick Answer
Twist Bioscience Corp reported Operating Income Loss of -$136.26 million for the year ending 2025.
- Twist Bioscience Corp showed an increase of +38.3% in Operating Income Loss from 2024 to 2025.
- This data is from Twist Bioscience Corp's annual report (Form 10-K), filed with the SEC on November 17, 2025.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: -$16.75 million | Q1 2018: -$16.62 million | Q2 2018: -$17.49 million | Q4 2018: -$22.90 million | Q1 2019: -$26.26 million | Q2 2019: -$28.12 million | Q4 2019: -$55.83 million | Q1 2020: -$32.09 million | Q2 2020: -$28.20 million | Q4 2020: -$32.79 million | Q1 2021: -$38.00 million | Q2 2021: -$42.12 million | Q4 2021: -$55.94 million | Q1 2022: -$60.80 million | Q2 2022: -$61.16 million | Q4 2022: -$44.63 million | Q1 2023: -$61.64 million | Q2 2023: -$60.78 million | Q4 2023: -$46.98 million | Q1 2024: -$48.89 million | Q2 2024: -$88.92 million | Q4 2024: -$34.64 million | Q1 2025: -$41.56 million | Q2 2025: -$30.12 million | Q4 2025: -$32.90 million.
- Over the full 9 years of available data (2017 to 2025), Twist Bioscience Corp's Operating Income Loss has declined by 133.0%.
- Historical annual values: Fiscal year 2025: -$136.26 million | Fiscal year 2024: -$220.83 million | Fiscal year 2023: -$217.16 million | Fiscal year 2022: -$234.78 million | Fiscal year 2021: -$152.73 million | Fiscal year 2020: -$140.08 million | Fiscal year 2019: -$108.85 million | Fiscal year 2018: -$70.56 million | Fiscal year 2017: -$58.48 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: